Canopy Growth (CGC) Long-Term Deferred Tax (2017 - 2020)

Canopy Growth (CGC) posted Long-Term Deferred Tax of $2.9 million for Q1 2020, down 90.82% sequentially from $32.0 million in Q1 2018.

Canopy Growth (CGC) Long-Term Deferred Tax (2017 - 2020) Analysis & Trends

Canopy Growth has reported Long-Term Deferred Tax for 3 years, with the latest figure at $2.9 million in Q1 2020.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $2.9 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $2.9 million (changed N/A YoY) and the FY2020 annual result came in at $2.9 million, changed N/A from the prior year.
Long-Term Deferred Tax retreated to $2.9 million in Q1 2020 per CGC's latest filing, from $32.0 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $32.0 million in Q1 2018 and troughed at $2.9 million in Q1 2020.
A 3-year average of $19.5 million and a median of $23.7 million in 2017 frame the typical range for Long-Term Deferred Tax.
The widest YoY moves for Long-Term Deferred Tax: up 35.42% in 2018, down 35.42% in 2018.
Over 3 years, Long-Term Deferred Tax stood at $23.7 million in 2017, then soared by 35.42% to $32.0 million in 2018, then slumped by 90.82% to $2.9 million in 2020.
According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $2.9 million, $32.0 million, and $23.7 million for Q1 2020, Q1 2018, and Q1 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.78 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.71 Bn	22.91 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.59 Bn	683.80 Mn
6	Viatris	18.72 Bn	17.83 Bn	1.46 Bn
7	Neurocrine Biosciences	15.57 Bn	15.18 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.97 Bn	-
10	Canopy Growth	437.04 Mn	190.03 Mn	16.08 Mn

Download Data